US pharmaceuticals giant AbbVie has raised its bid for Irish-domiciled Shire to £51.15 per share, causing the company’s share price to rocket, it was revealed today.
In a deal reminiscent of Pfizer’s failed AstraZeneca bid, it’s thought that the takeover would allow the US buyer to take advantage of attractive tax benefits and cost savings. The purchase would mean that at least 20% of the newly combined company’s shareholders would be non-US, opening up opportunities for tax inversion. With experts at Jefferies suggesting that that there is little product or portfolio-based rationale for the merger, many see this as a likely next step should the bid be accepted.
Last month, AbbVie made a series of offers to Shire, starting at £39.50 per share, but all were rejected. The latest bid marks another significant jump from the last offer, of £46.26 per share. Shire’s share price leapt following today’s announcement, peaking at £49.25 earlier today.
The US dollar and debt yields falling on the North Korea missile test, treasury being a top target for cyber criminals and why treasurers aren't into real-time payments all hit the latest headlines in the world of treasury this week. Don't miss our ten top news stories from around the world.
Chicago based Treasury Management System (TMS) vendor GTreasury and Sydney based risk and treasury management vendor Visual Risk have joined forces in a strategic alliance to ... read more
"Uncertainty is the enemy of deal-making", so it's no surprise that Europe and the Asia Pacific's insurance industry saw merger and acquisition deals fall in the first half of 2017.
One in five countries is set to hit their highest government debt levels in 17 years predicts Fitch, although there has still been a dramatic improvement in sovereign credit.